Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA

被引：0
|
作者：
Decker, Thomas
Brucker, Cosima
Engel, Anne
Fasching, Peter A.
Goehler, Thomas
Jackisch, Christian
Janssen, Jan
Koehler, Andreas
Luedtke-Heckenkamp, Kerstin
Lueftner, Diana
van Mackelenbergh, Marion
Marme, Frederik
Nusch, Arnd
Rautenberg, Beate
Reimer, Toralf
Schmidt, Marcus
Weide, Rudolf
Wimberger, Pauline
Roos, Christian
Woeckel, Achim
机构：
[1] Onkol Ravensburg, Ravensburg, Germany
[2] Paracelsus Med Univ, Univ Womens Hosp, Nurnberg, Germany
[3] Winicker Norimed GmbH, Nurnberg, Germany
[4] Univ Hosp Erlangen, Dept Obstet & Gynecol, Erlangen, Germany
[5] Onkozentrum Dresden Freiberg, Dresden, Germany
[6] Sana Klinikum Offenbach, Dept Obstet & Gynecol, Offenbach, Germany
[7] Med Studiengesell Nord West GmbH, Westerstede, Rhauderfehn, Germany
[8] Practice Hematol & Oncol, Langen, Germany
[9] Niels Stensen Kliniken, Dept Hematol & Oncol, Georgsmarienhutte, Germany
[10] Med Univ Brandenburg, Immanuel Klin Markische Schweiz, Buckow, Germany
[11] Univ Klinikum Schleswig Holstein, Kiel, Germany
[12] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany
[13] Practice Hematol & Internal Oncol, Velbert, Germany
[14] Univ Klinikum Freiburg, Freiburg, Germany
[15] Univ Klinikum Rostock, Rostock, Germany
[16] Johannes Gutenberg Univ Mainz, Klin & Poliklin Geburtshilfe & Frauengesundheit, Mainz, Germany
[17] InVO GbR, Koblenz, Germany
[18] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany
[19] Novartis Pharma GmbH, Nurnberg, Germany
[20] Univ Wurzburg, Dept Gynecol & Obstet, Wurzburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13050
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.
    Lueftner, Diana
    Brucker, Cosima
    Decker, Thomas
    Fasching, Peter A.
    Goehler, Thomas
    Jackisch, Christian
    Janssen, Jan
    Koehler, Andreas
    Luedtke-Heckenkamp, Kerstin
    Van Mackelenbergh, Marion
    Marme, Frederik
    Nusch, Arnd
    Rautenberg, Beate
    Reimer, Toralf
    Schmidt, Marcus
    Weide, Rudolf
    Wimberger, Pauline
    Nabieva, Naiba
    Roos, Christian
    Woeckel, Achim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA study
    Luftner, Diana
    Brucker, Cosima
    Decker, Thomas
    Fasching, Peter
    Gohler, Thomas
    Jackisch, Christian
    Janssen, Jan
    Kohler, Andreas
    Ludtke-Heckenkamp, Kerstin
    van Mackelenbergh, Marion
    Marme, Frederik
    Nusch, Arnd
    Rautenberg, Beate
    Reimer, Toralf
    Schmidt, Marcus
    Weide, Rudolf
    Wimberger, Pauline
    Nabieva, Naiba
    Roos, Christian
    Wockel, Achim
    CANCER RESEARCH, 2022, 82 (04)
  • [3] Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
    Neven, P.
    Petrakova, K.
    Bianchi, G. V.
    Merino, L. De la Cruz
    Jerusalem, G.
    Beck, J. T.
    Sonke, G. S.
    Chia, S.
    Brucker, S.
    Wang, Y.
    He, W.
    Lorenc, K. Rodriguez
    Su, F.
    Im, S-A.
    ANNALS OF ONCOLOGY, 2018, 29 : 113 - +
  • [4] Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) from the CompLEEment-1 trial
    Campone, M.
    De laurentiis, M.
    Zamagni, C.
    Kudryavcev, I.
    Agterof, M.
    Brown-Glaberman, U.
    Palacova, M.
    Chatterjee, S.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    Martin, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Ribociclib plus letrozole for first-line treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
    Andre, Fabrice
    Stemmer, Salomon M.
    Campone, Mario
    Petrakova, Katarina
    Paluch-Shimon, Shani
    Yap, Yoon-Sim
    Marschner, Norbert
    Chan, Arlene
    Villanueva, Cristian
    Hart, Lowell L.
    Arteaga, Carlos L.
    Sonke, Gabe S.
    Grischke, Eva-Maria
    Alba, Emilio
    Nusch, Arnd
    Yardley, Denise A.
    Jakobsen, Erik
    Blau, Sibel
    Tolaney, Sara M.
    Su, Faye
    He, Wei
    Germa, Caroline
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2017, 77
  • [6] Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study
    Wockel, Achim
    Brucker, Cosima
    Decker, Thomas
    Falbrede, Jorg
    Forstbauer, Helmut
    Gohler, Thomas
    Hoffmann, Oliver
    Jackisch, Christian
    Janssen, Jan
    Kohler, Andreas
    Ludtke-Heckenkamp, Kerstin
    Luftner, Diana
    Marme, Frederik
    Nusch, Arnd
    Reimer, Toralf
    Roos, Christian
    Schmidt, Marcus
    Weide, Rudolf
    Fasching, Peter
    CANCER RESEARCH, 2021, 81 (04)
  • [7] Treatment of elderly patients (pts; > 75 years) with 1st line ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL) or endocrine monotherapy (ET) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
    Decker, T.
    Brucker, C.
    Engel, A.
    Fasching, P. A.
    Goehler, T.
    Jackisch, C.
    Janssen, J.
    Koehler, A.
    Luedtke-Heckenkamp, K.
    Lueftner, D.
    van Mackelenbergh, M.
    Marme, F.
    Nusch, A.
    Rautenberg, B.
    Reimer, T.
    Schmidt, M.
    Weide, R.
    Wimberger, P.
    Figueroa, Maslanka S.
    Roos, C.
    Woeckel, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 168 - 169
  • [8] Ribociclib (RIB) plus fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen K. L.
    Im, Seock-Ah
    Fasching, Peter A.
    DeLaurentiis, Michelino
    Petrakova, Katarina
    Bianchi, Giulia Valeria
    Esteva, Francisco J.
    Martin, Miguel
    Pivot, Xavier
    Vidam, Gena
    Wang, Yingbo
    Lorenc, Cristina Karen Rodriguez
    Miller, Michelle Kristine
    Taran, Tanya
    Jerusalem, Guy Heinrich Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
    Chainitikun, Sudpreeda
    Long, James P.
    Rodriguez-Bautista, Ruben
    Iwase, Toshiaki
    Tripathy, Debu
    Fujii, Takeo
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 729 - 739
  • [10] RIBANNA Real-world evidence of ribociclib plus aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line therapy for postmenopausal women with HR+, HER2 advanced breast cancer (aBC)
    Woeckel, A.
    Fasching, P. A.
    Guderian, G.
    Heim, J.
    Jackisch, C.
    Luck, H-J
    Lueftner, D.
    Marme, F.
    Reimer, T.
    Decker, T.
    CANCER RESEARCH, 2019, 79 (04)
12345